In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry

@article{Bagai2014InHospitalSB,
  title={In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry},
  author={Akshay Bagai and Yongfei Wang and Tracy Y. Wang and Jeptha P Curtis and Hitinder S. Gurm and Binita Shah and Asim N. Cheema and Eric D. Peterson and Jorge Felix Saucedo and Christopher B. Granger and Matthew T. Roe and Deepak L. Bhatt and Robert L. McNamara and Karen P Alexander},
  journal={Circulation: Cardiovascular Interventions},
  year={2014},
  volume={7},
  pages={585–593}
}
Background—Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice. Methods and Results—We studied 47 040 patients with myocardial infarction treated with percutaneous coronary intervention, who received either clopidogrel or prasugrel within 24 hours of admission at 361 US hospitals… Expand
In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience
TLDR
In-hospital reloading and subsequent maintenance therapy with prasugrel in patients who received thrombolysis and a loading dose of clopidogrel appears to be as safe as in STEMI patients managed by primary PCI; however, larger studies are needed to verify these results. Expand
Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study
TLDR
In contemporary clinical practice, patients receiving prasugrel tend to have a lower‐risk profile compared with those receiving clopidogrel, and the lower ischemic and bleeding events associated with pr asugrel use were no longer evident after accounting for these baseline differences. Expand
Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study
TLDR
Few patients after MI with a recurrent ischemic event who were taking clopidogrel switched to a more potent P2Y12 inhibitor, even after stent thrombosis events, suggesting specific guidance is needed for patients who have recurrent isChemic events, particularly when closely spaced. Expand
Characteristics and clinical outcomes of patients with de-escalation from prasugrel to clopidogrel after acute myocardial infarction - Insights from the prospective Japan Acute Myocardial Infarction Registry (JAMIR).
TLDR
Although, patients with de-escalation from prasugrel to clopidogrel had higher bleeding risk profile than those continued on pr asugrel, post discharge ischemic and bleeding events were similar between patients with and without de- escalation. Expand
Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention
TLDR
The transition to clopidogrel with a dose of 75 mg at discharge, without a loading dose, appears to be a possible strategy and studies with greater statistical power are needed to confirm these findings. Expand
Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients.
  • Xuyun Wang, Shaozhi Xi, +4 authors Y. Chen
  • Medicine
  • European heart journal supplements : journal of the European Society of Cardiology
  • 2016
TLDR
In comparison with constant ticagrelor treatment, switching from clopidogrel to ticaragrelor in ischaemic high-risk patients confers similar antiplatelet efficacy and safety, while switching from ticAGrelor to clopIDogrel in is chaemic low- risk patients relates to lower hazard for bleeding events. Expand
Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronar
TLDR
Only one‐third of percutaneous coronary intervention–treated MI patients with high on‐clopidogrel platelet reactivity were switched to a more potent P2Y12 receptor inhibitor, and intensified antiplatelet therapy was associated with lower risk of ischemic events at 1 year among HPR patients. Expand
Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study.
TLDR
Despite the use of contemporary techniques, acute coronary syndrome patients who undergo complex PCI had significantly higher rates of 1-year MACE, and adjusted magnitude of treatment effects with prasugrel vs clopidogrel were consistent in complex and noncomplex PCI without evidence of interaction. Expand
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE‐ACS) obse
TLDR
Postdischarge ADPri switching occurred infrequently within the first year post‐MI and uncommonly was associated with MACEs or bleeding events. Expand
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients
TLDR
Patients receiving clopidogrel before admission for ACS and subsequently treated only medically are at higher risk for CV events versus those not previously receiving clanidine, and more potent antiplatelet inhibition with prasugrel versus clopIDogrel did not significantly reduce this risk. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRI
TLDR
Among acute coronary syndrome patients with planned percutaneous coronary intervention, treatment with prasugrel versus clopidogrel for up to 15 months is an economically attractive treatment strategy. Expand
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
TLDR
The benefit of therapy with clopidogrel in addition to aspirin in patients presenting with NSTE ACSs was significant irrespective of the timing of PCI and was associated with low absolute event rates for CV death/nonfatal MI. Expand
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
TLDR
Subjects with DM tended to have a greater reduction in ischemic events without an observed increase in TIMI major bleeding and therefore a greater net treatment benefit with prasugrel compared with clopidogrel, demonstrating that the more intensive oral antiplatelet therapy provided with pr asugrel is of particular benefit to patients with DM. Expand
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
TLDR
Despite an increase in observed bleeding, platelet transfusion, and surgical re-exploration for bleeding, prasugrel was associated with a lower rate of death after CABG compared with clopidogrel. Expand
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
TLDR
A clustering of adverse events in the initial 90 days after stopping clopidogrel among both medically treated and PCI-treated patients with ACS is observed, supporting the possibility of a clopIDogrel rebound effect. Expand
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
TLDR
In patients with STEMI undergoing PCI, prasugrel is more effective than clopidogrel for prevention of ischaemic events, without an apparent excess in bleeding. Expand
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
TLDR
In a real-life experience with contemporary antiplatelet treatment in ACS patients undergoing PCI, in-hospital switching represents common clinical practice and clinical factors and regional practice differences seem to affect this strategy's choice, while switching to a novel agent may be associated with higher risk of bleeding. Expand
Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry
TLDR
With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of pr asugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. Expand
Selecting Antiplatelet Therapy at the Time of Percutaneous Intervention for an Acute Coronary Syndrome: Weighing the Benefits and Risks of Prasugrel Versus Clopidogrel
TLDR
Considering both ischemia and bleeding risk, a large proportion of TRITON participants were predicted to experience net benefit with prasugrel, a rate that increased if patients more strongly preferred avoiding ischemic events than bleeding. Expand
Contemporary Use of Prasugrel in Clinical Practice: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium
TLDR
There has been a steady increase in the use of prasugrel with the drug being used in ≈22% of patients undergoing percutaneous coronary intervention by study end and may be a suitable target for focused quality improvement efforts. Expand
...
1
2
3
4
...